


disease (EAE-a model for multiple sclerosis) would be submitted in the supplemental response. A document referring to these experiments is attached hereto. If the examiner believes it necessary to submit these experiments in the form of an appropriate declaration, applicants will be happy to do so.

Finally, applicants also referred to Fishman et al, "An agonist to the A3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3 $\beta$  and NF- $\kappa$ B," Oncogene 23:2465-2471 (2004). A copy of this publication is also attached hereto.

Consideration of the present supplemental response with applicants' amendment of September 6, 2005, and reconsideration and allowance are earnestly solicited.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.  
Attorneys for Applicant(s)

By   
Roger L. Browdy  
Registration No. 25,618

RLB:rd/ma  
Telephone No.: (202) 628-5197  
Facsimile No.: (202) 737-3528  
G:\BN\C\cohn\Fishman9B\Pto\SupResponse.doc